DR. ALAN D LANGERAK MD NPI 1902853294

NPI Information

  • NPI: 1902853294
  • Provider Name: DR. ALAN D LANGERAK, MD
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 5430 LANDMARK LN
    PRESCOTT, AZ
    ZIP 86301
  • Phone: (928) 775-9430

Map and Directions

Get Directions

NPI Details

DR. Alan D Langerak, MD is a hematology and oncology internal medicine in Prescott, AZ with 36 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Alan D Langerak, MD NPI is 1902853294. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE
Graduation Year:1990

The provider's business location address is:

5430 LANDMARK LN
PRESCOTT, AZ
ZIP 86301-019
Phone: (928) 775-9430
Fax: (928) 775-9431

The NPI 1902853294 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, nivolumab, 1 mg (HCPCS:J9299)
  • Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, aprepitant, 1 mg (HCPCS:J0185)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, docetaxel, 1 mg (HCPCS:J9171)
  • Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
  • Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Cyclophosphamide, 100 mg (HCPCS:J9070)
  • Injection, potassium chloride, per 2 meq (HCPCS:J3480)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
  • Unclassified drugs (HCPCS:J3490)
  • Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
  • Drawing of blood for a medical problem (HCPCS:99195)
  • Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
  • Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Administration of chemotherapy into vein using push technique (HCPCS:96409)
  • Injection of drug or substance into vein (HCPCS:96374)
  • Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
  • Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
  • Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Nuclear medicine study whole body with ct scan (HCPCS:78816)
  • Declotting of central venous tube (HCPCS:36593)

The enumeration date for this NPI number is 5/30/2006 and was last updated on 10/10/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & Oncology19014OKLAHOMAYes

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.